A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

PHASE2UnknownINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

October 31, 2020

Conditions
Gastrointestinal Neuroendocrine Carcinomas
Interventions
DRUG

NAB paclitaxel

100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

Carboplatin

Trial Locations (3)

2065

Royal North Shore Hospital, St Leonards

3050

Royal Melbourne Hospital, Parkville

3220

Barwon Health, Geelong

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Specialised Therapeutics Australia

UNKNOWN

collaborator

Deakin University

OTHER

collaborator

Australasian Gastro-Intestinal Trials Group

NETWORK

lead

Barwon Health

OTHER_GOV